Adult Clinical Trials: LUNG

RTOG 0515:  LUNG

A Comparative Study of Gross Tumor Volume Definition With or Without PET Fusion for Patients With Non-Small Cell Lung Carcinoma

• Pathologically (histologically or cytologically) proven diagnosis of non-small cell lung cancer
• Stage IIA/IIB or stage IIIA/B disease; patients with local or regional nodal recurrence following surgery are eligible
• Zubrod Performance Status 0, 1, or 2 and age >=18
• Pregnant women are not eligible
• Women of childbearing potential and male participants must practice adequate contraception
• Patient must sign study-specific informed consent prior to study entry
• Patients with malignant pleural effusion are not eligible

RTOG 0229: LUNG

A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced Non-Small Cell Lung Cancer

• Stage IIIA(T1-3 N2) or Stage IIIB (N3 excluding supraclavicular involvement ) by biopsy or cytology.  Pancoast tumors are eligible if pathologic evidence of mediastinal nodal disease is present.

Treatment:

Induction Chemoradiation: Paclitaxel and Carboplatin 1x/week for 6 weeks plus Concurrent RT 1.8Gy/day, 5x/week, for a total of 50.4Gy in 28 fractions plus RT boost: 1.8Gy/day, 5x/week, for a total of l0.8Gy in 6 fractions.  Reassessment: 4 weeks post Induction Chemoradiation:  Resection: Consolidation Chemotherapy: Paclitaxel and Carboplatin q 21 days x 2.